{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:42:36Z","timestamp":1768002156855,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T00:00:00Z","timestamp":1369094400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Spinal Cord"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1038\/sc.2013.42","type":"journal-article","created":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T09:17:59Z","timestamp":1369127879000},"page":"637-641","source":"Crossref","is-referenced-by-count":7,"title":["The use of oxybutynin in patients treated by means of botulinum neurotoxin A for neurogenic detrusor overactivity: an observational study"],"prefix":"10.1038","volume":"51","author":[{"given":"E","family":"Finazzi-Agr\u00f2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Topazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Perugia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Finita Celso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"De Nunzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Del Popolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,21]]},"reference":[{"key":"BFsc201342_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Urology 2003; 61: 37\u201349.","journal-title":"Urology"},{"key":"BFsc201342_CR2","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/00002060-200112000-00008","volume":"80","author":"BL Hicken","year":"2001","unstructured":"Hicken BL, Putzke JD, Richards JS . Bladder management and quality of life after spinal cord injury. Am J PhysMed Rehabil 2001; 80: 916\u2013922.","journal-title":"Am J PhysMed Rehabil"},{"key":"BFsc201342_CR3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0094-0143(21)00504-8","volume":"20","author":"I Perkash","year":"1993","unstructured":"Perkash I . Long-term urologic management of the patient with spinal cord injury. Urol Clin North Am 1993; 20: 423\u2013434.","journal-title":"Urol Clin North Am"},{"key":"BFsc201342_CR4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11934-007-0032-6","volume":"8","author":"SA MacDiarmid","year":"2007","unstructured":"MacDiarmid SA . How to choose the initial drug treatment for overactive bladder. Curr Urol Rep 2007; 8: 364\u2013369.","journal-title":"Curr Urol Rep"},{"key":"BFsc201342_CR5","first-page":"182","volume":"10","author":"MJ Kennelly","year":"2008","unstructured":"Kennelly MJ, Devoe WB . Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol 2008; 10: 182\u2013191.","journal-title":"Rev Urol"},{"key":"BFsc201342_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1464-410X.2006.06258.x","volume":"98","author":"SM Finney","year":"2006","unstructured":"Finney SM, Andersson KE, Gillespie JI, Stewart LH . Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 2006; 98: 503\u2013507.","journal-title":"BJU Int"},{"key":"BFsc201342_CR7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1056\/NEJM200003023420918","volume":"342","author":"B Schurch","year":"2000","unstructured":"Schurch B, Schmid DM, Stohrer M . Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342: 665.","journal-title":"N Engl J Med"},{"key":"BFsc201342_CR8","volume-title":"Incontinence","author":"P Abrams","year":"2008","unstructured":"Abrams P, Cardozo L, Khoury S, Wein A eds.. Incontinence ed Plymouth, UK: Health Publication Ltd. 2008."},{"key":"BFsc201342_CR9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011; 60: 742\u2013750.","journal-title":"Eur Urol"},{"key":"BFsc201342_CR10","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.juro.2012.01.125","volume":"187","author":"D Ginsberg","year":"2012","unstructured":"Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W et al. Phase 3 efficacy and tolerability study of onabotulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012; 187: 2131\u20132139.","journal-title":"J Urol"},{"key":"BFsc201342_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.eururo.2007.10.013","volume":"53","author":"G Karsenty","year":"2008","unstructured":"Karsenty G, Denys P, Amarenco G, De Seze M, Gam\u00e9 X, Haab F et al. (BotoxW) Intradetrusor injections in adults with neurogenic detrusor overactivity\/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008; 53: 275\u2013287.","journal-title":"Eur Urol"},{"key":"BFsc201342_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E Von Elm","year":"2008","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP . STROBE initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344\u2013349.","journal-title":"J Clin Epidemiol"},{"key":"BFsc201342_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.eururo.2003.12.004","volume":"45","author":"A Reitz","year":"2004","unstructured":"Reitz A, Stohrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45: 510\u2013515.","journal-title":"Eur Urol"},{"key":"BFsc201342_CR14","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/01.ju.0000169480.43557.31","volume":"174","author":"R Popat","year":"2005","unstructured":"Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P . A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005; 174: 984\u2013989.","journal-title":"J Urol"},{"key":"BFsc201342_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1310\/1640-XEPP-Y33E-TMK8","volume":"8","author":"MJ Kennelly","year":"2003","unstructured":"Kennelly MJ, Kang J . Botulinum-A toxin injections as a treatment for refractory detrusor hyperreflexia. Top Spinal Cord Inj Rehabil 2003; 8: 46\u201353.","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"BFsc201342_CR16","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","volume":"164","author":"B Schurch","year":"2000","unstructured":"Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D . Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692\u2013697.","journal-title":"J Urol"},{"key":"BFsc201342_CR17","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","volume":"60","author":"A Mangera","year":"2011","unstructured":"Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxin A) and dysport (abobotulinumtoxin A). Eur Urol 2011; 60: 784\u2013795.","journal-title":"Eur Urol"}],"container-title":["Spinal Cord"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/sc201342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/sc201342","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/sc201342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:25:17Z","timestamp":1684621517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/sc201342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,21]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["BFsc201342"],"URL":"https:\/\/doi.org\/10.1038\/sc.2013.42","relation":{},"ISSN":["1362-4393","1476-5624"],"issn-type":[{"value":"1362-4393","type":"print"},{"value":"1476-5624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,21]]}}}